| 13.3°C Dublin

Close

Premium

Perrigo's €1.64bn tax battle with Revenue set to begin in June

Boss says company looks forward to its day in court after delays due to virus

Close

'Perrigo's judicial review is challenging Revenue's tax assessment as the company feels it had "legitimate expectations" based on prior tax returns to Revenue.'

'Perrigo's judicial review is challenging Revenue's tax assessment as the company feels it had "legitimate expectations" based on prior tax returns to Revenue.'

'Perrigo's judicial review is challenging Revenue's tax assessment as the company feels it had "legitimate expectations" based on prior tax returns to Revenue.'

A judicial review into a €1.64bn tax assessment handed to Perrigo, a US pharmaceutical company headquartered in Ireland, is to move ahead at the beginning of June having been delayed due to Covid-19.

Last week, Murray Kessler, chief executive of Perrigo, which is listed on the New York Stock Exchange with a $7.4bn (€6.78bn) market capitalisation, said the judicial review of Revenue's tax assessment would take place on June 3. The case had been delayed due to Covid-19, with Kessler stating he thought it may have been pushed out until the end of the year.

Kessler said he was looking forward to Perrigo's day in court and was confident of its position on the case.